Chengdu Kanghua Biological Products Co., Ltd.

Company Profile

1.Outstanding products and technologies Core product Rabies Vaccine (Human diploid cell) for Human Use, Freeze-dried, adopting the advanced domestic technology "100L big volume bioreactor microcarrier scale cultivation, the amplification diploid cell technology" and chromatographic purification, is the first diploid cell rabies vaccine introduced to market, breaking the limitation of domestic rabies vaccine using animal cells. It exhibits the advantages of "no introduction of animal-derived cell residual DNA and animal-derived cell protein", high safety, good immunogenicity and long protection duration. 2.Standardized and strict product quality control The company has always adhered to the concept of "quality is the first lifeline of the enterprise", carried out the quality policy of "leadership attention, full participation, scientific and rigorous, continuous improvement, customer satisfaction", and established a quality assurance system independent from production management. From the product application, filing, material into the factory, production process, release for examination and approval, market complaints, to adverse reaction monitoring, a comprehensive quality management is conducted throughout the life cycle of a product. At the same time, periodic self-inspection, initiatives to collect market information feedbacks, reviews of the effectiveness and applicability of the quality management system are performed, so as to improve the quality inspection and supervision of product realization process. 3.Excellent R&D team and leading R&D platform layout As a comprehensive vaccine enterprise focusing on biomedical field and focusing on research and development, the company has an efficient, stable and experienced R&D team, who independently give birth to the entire production process and technology of the company's existing products. At the same time, the company has established a multi-dimensional R&D incentive mechanism, which is conducive to mobilize the enthusiasm of R&D specialists. The company’s pipeline is centered on the construction of the vaccine R&D platform, and the company has set up the recombinant protein VLP vaccine platform, polyglycoprotein conjugate vaccine platform, live attenuated vaccine platform, inactivated vaccine platform, novel vaccine adjuvant platform, etc. 4.Professional and stable core management team The company has a stable management team. Core members have been engaged in the R&D, production and sales of biomedical products for a long time, with rich experience and knowledge in the biomedical fields, and a profound experience and cognition of the development level and trend of the industry. Under the leadership of the professional and stable management team, the company has formed a scientific and reasonable business philosophy and established an efficient business management system. The company's management team can quickly and reasonably respond to changes in the internal and external environment, which leads to the long-term development of the company.